Visceral Leishmaniasis Clinical Trial
Official title:
An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
Verified date | July 2020 |
Source | Drugs for Neglected Diseases |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open label, Phase III, randomized, controlled, parallel arm multicentre non-inferiority clinical trial to compare the efficacy and safety of two combination regimens of Miltefosine and Paromomycin with the standard SSG-PM for the treatment of primary adult and children VL patients in Eastern Africa.
Status | Completed |
Enrollment | 439 |
Est. completion date | December 11, 2020 |
Est. primary completion date | December 11, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 50 Years |
Eligibility | Inclusion Criteria: - Patients with clinical signs and symptoms of VL and confirmatory parasitological microscopic diagnosis - Patients aged 4 to < 50 years who are able to comply with the study protocol. - Patients for whom written informed consent has been obtained (if aged 18 years and over) or signed by parents(s) or legal guardian for patients under 18 years of age. In the case of minors, assent from the children also needs to be obtained as per each country regulatory requirements Exclusion Criteria: - Patients who are relapse cases - Patients with Para-Kala azar dermal leishmaniasis grade 3 - Patients who have received any anti-leishmanial drugs in the last 6 months - Patients with severe malnutrition (for children aged <5 years: weight-for-height WHO reference curves by sex, z score <-3; for children patients 5-18 years: BMI-for-age WHO reference curves by sex, z score < -3; for adults >18 years: BMI < 16)* - Patients with positive HIV diagnosis - Patients with previous history of hypersensitivity reaction or known drug class allergy to any of the study treatments - Patients with previous history of cardiac arrhythmia or with a clinically significant abnormal ECG - Patients suffering from a concomitant severe infection such as TB, schistosomiasis or any other serious underlying disease (e.g. cardiac, renal, hepatic) or chronic condition which would preclude evaluation of the patient's response to study medication - Pregnant or lactating women - Female patients of child bearing age who do not accept to have a pregnancy test done at screening and/or who do not agree to use contraception from treatment period until 5 months after the end of treatment (see section 15.2) - Patients with haemoglobin < 5g/dl - Patients with signs of severe VL according to Investigator's judgement, requiring an indication for AmBisome therapy based on the clinical manifestations (such as jaundice, bleeding, edema) and clinically significant abnormalities in the following laboratory parameters: haemoglobin, WBC, platelets, liver enzymes (ALT and AST), total bilirubin and creatinine - Patients with pre-existing hearing loss based on audiometry at baseline - Patients who cannot comply with the planned scheduled visits and procedures of the study protocol - Note: for Ethiopia only: Patients with severe malnutrition (for patients 4-18 years: MUAC cut-off based on MUAC-for-height reference table; for patients > 18 years: MUAC < 170 mm) |
Country | Name | City | State |
---|---|---|---|
Ethiopia | Abdurafi MSF Health Center | Abderafi | Amhara |
Ethiopia | University Hospital of Gondar | Gondar | |
Kenya | Kacheliba Hospital | Kapenguria | West Pokot |
Sudan | El Hassan Centre for Tropical Medicine | Doka | Gedaref |
Sudan | Tabarak Allah MSF Hospital | Gadarif | Gedaref |
Sudan | Um El Kher Hospital | Gedaref | |
Uganda | Amudat Hospital | Amudat | Karamoja |
Lead Sponsor | Collaborator |
---|---|
Drugs for Neglected Diseases | Kenya Medical Research Institute, Makerere University, The Institute of Endemic Diseases (IEND), University of Khartoum, The Netherlands Cancer Institute, University of Gondar |
Ethiopia, Kenya, Sudan, Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Definitive Cure | Cure at 6 months follow up defined as absence of clinical signs and symptoms of VL at D210 and no requirement for rescue treatment during the trial (e.g. no relapse or initial treatment failure). | 6 months follow-up (Day 210) | |
Secondary | Incidence of Treatment-Emergent Adverse Events | Frequency of SAEs and AEs requiring treatment discontinuation
Frequency and severity of adverse events from the start of treatment through the last visit, at day 210. |
From Screening to day 210 | |
Secondary | Initial cure at day 28 | Initial cure: cure at the end of treatment (Day 28), defined as recovery of clinical signs and symptoms; absence of parasites (microscopy) and no rescue treatment administered up to and including Day 28.
Probable cure: absence of clinical signs and symptoms of VL at D56 and no prior requirement for rescue medication. |
Initial cure: day 28; Probable cure: day 56 | |
Secondary | Pharmacokinetics of paromomycin and miltefosine | Total and partial blood plasma exposure to paromomycin and miltefosine defined as the area under the concentration-time curve | During treatment, at 1 month (day 56) and 6 months (day 210) follow-up | |
Secondary | Pharmacodynamics | Blood parasite clearance over time (qualitative and quantitative), as measured by qPCR from blood samples | From baseline until day 210, and at any suspicion of relapse during the trial. | |
Secondary | Compliance to miltefosine treatment in an outpatient setting | Compliance to MF treatment in an outpatient setting will be assessed through patients' hospital records history, drug accountability and PK measurements. | Day 15 to day 28 miltefosine treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02839603 -
Asymptomatic Leishmania Infection in HIV Patients
|
||
Completed |
NCT00370825 -
Combination Chemotherapy for the Treatment of Indian Kala-Azar
|
Phase 2 | |
Recruiting |
NCT05426577 -
Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
|
||
Completed |
NCT01069198 -
A Community Trial for Visceral Leishmaniasis (VL)
|
N/A | |
Completed |
NCT01032187 -
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
|
Phase 4 | |
Completed |
NCT00371995 -
Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar
|
Phase 2 | |
Completed |
NCT00604955 -
Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis
|
Phase 4 | |
Completed |
NCT00342823 -
Immunogenetics of Visceral Leishmaniasis
|
N/A | |
Completed |
NCT04003532 -
LAMP Assay for the Diagnosis of Visceral Leishmaniasis
|
||
Terminated |
NCT01980199 -
Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan
|
Phase 2 | |
Completed |
NCT00255567 -
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
|
Phase 3 | |
Not yet recruiting |
NCT06118749 -
Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study
|
||
Recruiting |
NCT04342715 -
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
|
||
Completed |
NCT02431143 -
Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa
|
Phase 2 | |
Completed |
NCT01122771 -
Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh
|
Phase 3 | |
Completed |
NCT03636659 -
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
|
Phase 1 | |
Not yet recruiting |
NCT01566552 -
Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis
|
Phase 4 | |
Completed |
NCT00696969 -
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
|
Phase 3 | |
Completed |
NCT00318721 -
Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar
|
N/A | |
Completed |
NCT00216346 -
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
|
Phase 3 |